Emergent Biosolutions EBS Remaining performance obligations related to customer contracts that are unsatisfied or partially unsatisfied

Remaining performance obligations related to customer contracts that are unsatisfied or partially unsatisfied at other companies

Thermo Fisher ScientificTMO

——

West Pharmaceutical ServicesWST

——

Charles River LaboratoriesCRL

——

Ginkgo BioworksDNA

——

Rapid7RPD

——

Baxter InternationalBAX

——

Other financials

Income statement

See full

Revenue$156.1M-29.7%

Gross profit$84.1M-37.1%

Operating income$10.5M-79.0%

Net income$6.8M-90.0%

EPS (diluted)$0.07-94.1%

Balance sheet

See full

Cash & equivalents$161.5M+5.7%

Total debt$584.6M-13.1%

Total equity$523.1M-5.4%

Total assets$1.3B-7.4%

Cash flow

See full

Operating cash flow-$33.8M-202%

CapEx$2.4M-33.3%

Free cash flow-$36.2M-145%

Valuation

See full

Market cap$411.74M+22.0%

Enterprise value$834.84M-2.6%

P/E3.6×—

P/S0.6×+0.3×

Profitability

See full

Gross margin54.2%+19.0pp

Operating margin15%+10.3pp

Net margin9.6%+5.8pp

FCF margin20.8%—

Returns & leverage

See full

Return on equity13.9%+8.1pp

Debt / equity1.1×-0.1×

Current ratio4.3×-2.0×

Where this comes from

Reported directly by Emergent Biosolutions in its filing.

Tagged under the XBRL concept us-gaap:RevenueRemainingPerformanceObligation.

The official record: Emergent Biosolutions’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Emergent Biosolutions's remaining performance obligations related to customer contracts that are unsatisfied or partially unsatisfied.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Emergent Biosolutions's remaining performance obligations related to customer contracts that are unsatisfied or partially unsatisfied?: Emergent Biosolutions (EBS) reported remaining performance obligations related to customer contracts that are unsatisfied or partially unsatisfied of $248M in Q1 2026.
How has Emergent Biosolutions's remaining performance obligations related to customer contracts that are unsatisfied or partially unsatisfied changed year-over-year?: Emergent Biosolutions's remaining performance obligations related to customer contracts that are unsatisfied or partially unsatisfied decreased by 8.3% year-over-year, from $270.4M to $248M.